Travers Smith corporate partner Andrew Gillen is leading a team advising Panmure Gordon & Co Limited as broker, sole bookrunner and proposed nominated adviser and Daniel Stewart & Company plc as current nominated adviser in connection with the proposed reverse takeover of Platinum NanoChem Sdn. Bhd. by AIM listed Biofutures International plc and the related placing of new ordinary shares.

Platinum NanoChem Sdn. Bhd. is a global nanotechnology company which designs, formulates, manufactures and markets a range of graphene enhanced speciality chemicals and advanced materials that demonstrate improved performance characteristics when compared to existing products within the chemicals and materials market.

The placing is expected to raise £32.5 million (before expenses) which will be used to implement the enlarged group's expansion strategy and for working capital purposes. The placing and the acquisition are subject to shareholder approval.

Following completion of the acquisition and the placing, Biofutures International will be renamed Graphene NanoChem Plc.

http://www.traverssmith.com/news-publications/press-releases/travers-sm…